Novozymes A/S

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Goldman Sachs has a list of global stocks it expects will outperform in 2025. In particular, the investment bank is bullish on three names – Novozymes, Kawasaki Heavy Industries, and PetroChina.

Top 3 global stocks poised for 40% gains by 2025

Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Officer Rainer Lehmann - Chief Financial Officer Jacob Paulsen - Executive Vice President, Food & Beverage Biosolutions Amy Byrick - Executive Vice President, Human Health Biosolutions Tina Fano - Executive Vice President, Planetary Health Biosolutions Claus Crone Fuglsang - Chief Scientific Officer Conference Call Participants Alex Jones - Bank of America Thomas Lind Petersen - Nordea Charles Eden - UBS Søren Samsøe - SEB Chetan Udeshi - JPMorgan Lars Topholm - Carnegie Investment Bank Nicola Tang - BNP Paribas Exane Georgina Fraser - Goldman Sachs Charles Bentley - Jefferies Operator Welcome to the Novonesis Interim Report for the First Nine Months of 2024 Conference Call. Throughout, all participants will be in listen-only mode and afterwards there will be a question-and-answer session.

Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript

Novonesis, formed from Chr. Hansen and Novozymes, shows promising growth but remains overvalued with a current P/E of 33x, down from 40x. Organic sales for 9M24 rose 9%, driven by volume and pricing, with new products and emerging market growth contributing significantly. Despite strong performance, risks include reliance on GDP-like growth in core markets and volatility in energy/bioenergy sectors.

Novonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade)

Axalta Coating Systems

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Axalta Coating Systems (AXTA) or Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?

AXTA vs. NVZMY: Which Stock Is the Better Value Option?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Novozymes (NVZMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Novozymes (NVZMY) Should Keep going

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Axalta Coating Systems (AXTA) and Novozymes A/S (NVZMY). But which of these two stocks is more attractive to value investors?

AXTA vs. NVZMY: Which Stock Should Value Investors Buy Now?

H.B. Fuller

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and Novozymes A/S (NVZMY).

FUL or NVZMY: Which Is the Better Value Stock Right Now?

Here is how Novozymes A/S (NVZMY) and Vizsla Silver Corp. (VZLA) have performed compared to their sector so far this year.

Is Novozymes (NVZMY) Stock Outpacing Its Basic Materials Peers This Year?

Novozymes A/S (OTCPK:NVZMF) Q2 2024 Results Conference Call August 28, 2024 3:00 AM ET Company Participants Tobias Björklund - Head of Investor Relations Ester Baiget - President & CEO Rainer Lehmann - Executive VP & CFO Tina Fano - Executive Vice President of Planetary Health Biosolutions Jacob Paulsen - Executive Vice President of Food & Beverage Biosolutions Amy Byrick - Executive Vice President of Human Health Biosolutions Claus Crone Fuglsang - Chief Scientific Officer Conference Call Participants Charles Eden - UBS Alex Jones - Bank of America Søren Samsøe - SEB Alex Sloane - Barclays Chetan Udeshi - JPMorgan Lars Topholm - Carnegie Sebastian Bray - Berenberg André Thormann - Danske Bank Georgina Fraser - Goldman Sachs Tobias Björklund Thank you, operator, and welcome, everyone, to Novonesis' conference call for the first half year of 2024. My name is Tobias Björklund, as mentioned, and I'm heading up the Investor Relations here at Novonesis.

Novozymes A/S (NVZMF) Q2 2024 Earnings Call Transcript

Ashland Global Hlds

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?

ASH or NVZMY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Ashland (ASH) or Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

ASH vs. NVZMY: Which Stock Is the Better Value Option?

Mativ Inc

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Mativ Holdings (MATV) or Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV vs. NVZMY: Which Stock Should Value Investors Buy Now?

Investors interested in Chemical - Specialty stocks are likely familiar with Mativ Holdings (MATV) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV or NVZMY: Which Is the Better Value Stock Right Now?

Here is how Novozymes A/S (NVZMY) and Paladin Energy (PALAF) have performed compared to their sector so far this year.

Are Basic Materials Stocks Lagging Novozymes (NVZMY) This Year?

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Mativ Holdings (MATV) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

MATV vs. NVZMY: Which Stock Is the Better Value Option?

An extraordinary shareholders' meeting of Novozymes A/S will be held on  Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.

Invitation to an extraordinary shareholders' meeting of Novozymes A/S

This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.

The Novozymes Report 2023

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No.

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.

Legacy Novozymes delivers solid last full-year results

January 29, 2024 – Company announcement no. 2 Please see attachment.

Completion of the combination between Novozymes and Chr. Hansen

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet. COPENHAGEN, Denmark – January 29, 2024. On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. All regulatory approvals and registrations are now in place and the proposed combination is successfully completed following the final registration with the Danish Business Authority today. Ester Baiget, President and CEO of Novonesis, says:

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

January 26, 2024 – Company announcement no. 1 Please see attachment.

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

Investors with an interest in Chemical - Specialty stocks have likely encountered both Axalta Coating Systems (AXTA) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?

AXTA or NVZMY: Which Is the Better Value Stock Right Now?

December 20, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com Attachment 2023_South Korean merger approval granted

News for Novozymes A/S Stock (NVZMY)